The legacy of general health and science information has long served as a foundation for public understanding of disease prevention and wellness. Within this broad context, mass production environments have historically been examined for their potential to influence population health through exposure to various materials and processes. As industrial practices evolve, the focus has increasingly shifted toward identifying specific occupational hazards that may arise from novel therapeutic agents entering the production chain. In recent years, the development and manufacturing of immunotherapeutic drugs, such as those targeting immune checkpoint pathways, have expanded significantly. This growth introduces new considerations for workers involved in the synthesis, formulation, and handling of these compounds. Among these agents, Avelumab has emerged as a notable example, particularly in relation to its use in treating certain malignancies. The transition from general health education to occupational exposure concern becomes pertinent when considering the potential risks associated with chronic, low-level contact with active pharmaceutical ingredients during mass production. Specifically, the handling of Avelumab in manufacturing settings raises questions about unintended exposure and its possible link to Merkel Cell Carcinoma risk. While the therapeutic benefits are well-documented for patients, the occupational context demands a separate evaluation of exposure thresholds and protective measures. This pivot from broad health science to targeted industrial hygiene underscores the need for rigorous monitoring protocols in facilities where such biologics are produced.
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/33439294/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who are refractory to avelumab, treatment options are limited. In Europe, approved systemic therapies are restricted to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). In avelumab-refractory patients, combined therapy with ipilimumab and nivolumab has shown activity. In a retrospective study of five patients treated at three academic sites in Germany, three out of five patients responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG further supports the use of ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/).
Prognosis-related considerations for affected patients include the potential for durable responses with avelumab, but also the possibility of progression and the need for subsequent therapies such as ipilimumab plus nivolumab. The timeline between exposure and documented harm is variable; immune-related adverse events can occur at any time during treatment, as illustrated by the case of sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). The efficacy of avelumab is typically assessed after several cycles of treatment, with objective responses observed in about one-third of patients in the JAVELIN Merkel 200 trial (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab, like other checkpoint inhibitors, can cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). The hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case highlights the need for monitoring for irAEs during treatment. Regarding risk anchors, the adequacy of warnings about avelumab and MCC is supported by the drug's approval based on clinical trial data and its established role as a first-line therapy for metastatic MCC. However, the risk of progression in approximately 50% of patients underscores the need for clear communication about prognosis and alternative treatments.
Management of MCC in the context of avelumab therapy involves careful patient selection, monitoring for immune-related adverse events, and planning for potential progression. For patients who become refractory to avelumab, combination immunotherapy with ipilimumab and nivolumab may offer an alternative treatment pathway (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In summary, avelumab is a key therapeutic option for metastatic MCC, with evidence of efficacy in a subset of patients. However, the risk of progression and immune-related adverse events requires careful management and patient counseling. Occupational exposure concerns, while not the primary focus of this article, highlight the need for protective measures in manufacturing settings where avelumab is handled.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The prognosis for MCC patients treated with avelumab varies. In the JAVELIN Merkel 200 trial, approximately one-third of patients with chemotherapy-refractory metastatic MCC achieved objective responses (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, about 50% of patients with advanced MCC progress on immune checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/35877101/). Durable responses are possible, but progression remains a significant concern.
For patients refractory to avelumab, combination therapy with ipilimumab and nivolumab has shown activity. A retrospective study reported responses in three out of five patients (https://pubmed.ncbi.nlm.nih.gov/33439294/), and a multicenter study from the ADOREG registry supports this approach (https://pubmed.ncbi.nlm.nih.gov/36450381/).
Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system. One reported case involved hypercalcemia secondary to reactivation of sarcoidosis, which was managed with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). Monitoring for irAEs is essential during treatment.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.